A recent study identified the expansion of neutrophils, called IFNactive neutrophils, with a distinct IFN signaling signature as the main target of beneficial GC treatment effects in patients with COVID-19, and this expansion may also stem from GCs selectively targeting the Th1/IFN-γ pathogenic cytokine pathway (40). The gene discussed is IFNA1; the disease is COVID-19.